Drug safety evaluation of ropinirole prolonged release

Research output: Contribution to journalArticle

Abstract

Introduction: The need for multiple administrations and a difficult titration schedule has always represented a limit in the use of dopamine agonists in the treatment of early Parkinson's disease. To avoid these problems, Ropinirole prolonged release (RPR), a non-ergoline dopamine receptor agonist that can be taken once a day, has been formulated. The prolonged release formulation has higher patient compliance due to a simpler and fastest titration schedule; the once-a-day administration makes this molecule especially suitable for young Parkinsonian patients who are still working and having an active lifestyle. Areas covered: In this paper, we will review ropinirole's mechanism of action including pharmacokinetics and pharmacodynamic data and the results of the main clinical studies in early and advanced PD patients. We will also discuss safety data shown during the experimental phase and after RPR commercialization. This article reviews the use of RPR in early and advanced Parkinsonian patients. Medical literature on the use of RPR in Parkinson's disease was identified using MEDLINE and the reference lists of published articles. Expert opinion: RPR is effective in the treatment of patients with early Parkinson's disease; in advanced Parkinsonian patients, the amount of daily off-time significantly decreases, improving the mean on time. RPR has also demonstrated to be effective in ameliorating the quality of sleep without increasing the occurrence of daily sleepiness and nocturnal psychosis. RPR was generally well tolerated in both early and advanced Parkinsonian patients.

Original languageEnglish
Pages (from-to)383-389
Number of pages7
JournalExpert Opinion on Drug Safety
Volume13
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Drug Evaluation
Safety
Parkinson Disease
Dopamine Agonists
Appointments and Schedules
ropinirole
Expert Testimony
Patient Compliance
MEDLINE
Psychotic Disorders
Life Style
Sleep
Pharmacokinetics
Therapeutics

Keywords

  • Dopamine agonists
  • Parkinson's disease
  • Ropinirole prolonged release
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Drug safety evaluation of ropinirole prolonged release. / Stocchi, Fabrizio; Radicati, Fabiana G.; Torti, Margherita.

In: Expert Opinion on Drug Safety, Vol. 13, No. 3, 03.2014, p. 383-389.

Research output: Contribution to journalArticle

@article{fa872817ce1247d1b7e649b9ab3c09c0,
title = "Drug safety evaluation of ropinirole prolonged release",
abstract = "Introduction: The need for multiple administrations and a difficult titration schedule has always represented a limit in the use of dopamine agonists in the treatment of early Parkinson's disease. To avoid these problems, Ropinirole prolonged release (RPR), a non-ergoline dopamine receptor agonist that can be taken once a day, has been formulated. The prolonged release formulation has higher patient compliance due to a simpler and fastest titration schedule; the once-a-day administration makes this molecule especially suitable for young Parkinsonian patients who are still working and having an active lifestyle. Areas covered: In this paper, we will review ropinirole's mechanism of action including pharmacokinetics and pharmacodynamic data and the results of the main clinical studies in early and advanced PD patients. We will also discuss safety data shown during the experimental phase and after RPR commercialization. This article reviews the use of RPR in early and advanced Parkinsonian patients. Medical literature on the use of RPR in Parkinson's disease was identified using MEDLINE and the reference lists of published articles. Expert opinion: RPR is effective in the treatment of patients with early Parkinson's disease; in advanced Parkinsonian patients, the amount of daily off-time significantly decreases, improving the mean on time. RPR has also demonstrated to be effective in ameliorating the quality of sleep without increasing the occurrence of daily sleepiness and nocturnal psychosis. RPR was generally well tolerated in both early and advanced Parkinsonian patients.",
keywords = "Dopamine agonists, Parkinson's disease, Ropinirole prolonged release, Safety",
author = "Fabrizio Stocchi and Radicati, {Fabiana G.} and Margherita Torti",
year = "2014",
month = "3",
doi = "10.1517/14740338.2014.870152",
language = "English",
volume = "13",
pages = "383--389",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Drug safety evaluation of ropinirole prolonged release

AU - Stocchi, Fabrizio

AU - Radicati, Fabiana G.

AU - Torti, Margherita

PY - 2014/3

Y1 - 2014/3

N2 - Introduction: The need for multiple administrations and a difficult titration schedule has always represented a limit in the use of dopamine agonists in the treatment of early Parkinson's disease. To avoid these problems, Ropinirole prolonged release (RPR), a non-ergoline dopamine receptor agonist that can be taken once a day, has been formulated. The prolonged release formulation has higher patient compliance due to a simpler and fastest titration schedule; the once-a-day administration makes this molecule especially suitable for young Parkinsonian patients who are still working and having an active lifestyle. Areas covered: In this paper, we will review ropinirole's mechanism of action including pharmacokinetics and pharmacodynamic data and the results of the main clinical studies in early and advanced PD patients. We will also discuss safety data shown during the experimental phase and after RPR commercialization. This article reviews the use of RPR in early and advanced Parkinsonian patients. Medical literature on the use of RPR in Parkinson's disease was identified using MEDLINE and the reference lists of published articles. Expert opinion: RPR is effective in the treatment of patients with early Parkinson's disease; in advanced Parkinsonian patients, the amount of daily off-time significantly decreases, improving the mean on time. RPR has also demonstrated to be effective in ameliorating the quality of sleep without increasing the occurrence of daily sleepiness and nocturnal psychosis. RPR was generally well tolerated in both early and advanced Parkinsonian patients.

AB - Introduction: The need for multiple administrations and a difficult titration schedule has always represented a limit in the use of dopamine agonists in the treatment of early Parkinson's disease. To avoid these problems, Ropinirole prolonged release (RPR), a non-ergoline dopamine receptor agonist that can be taken once a day, has been formulated. The prolonged release formulation has higher patient compliance due to a simpler and fastest titration schedule; the once-a-day administration makes this molecule especially suitable for young Parkinsonian patients who are still working and having an active lifestyle. Areas covered: In this paper, we will review ropinirole's mechanism of action including pharmacokinetics and pharmacodynamic data and the results of the main clinical studies in early and advanced PD patients. We will also discuss safety data shown during the experimental phase and after RPR commercialization. This article reviews the use of RPR in early and advanced Parkinsonian patients. Medical literature on the use of RPR in Parkinson's disease was identified using MEDLINE and the reference lists of published articles. Expert opinion: RPR is effective in the treatment of patients with early Parkinson's disease; in advanced Parkinsonian patients, the amount of daily off-time significantly decreases, improving the mean on time. RPR has also demonstrated to be effective in ameliorating the quality of sleep without increasing the occurrence of daily sleepiness and nocturnal psychosis. RPR was generally well tolerated in both early and advanced Parkinsonian patients.

KW - Dopamine agonists

KW - Parkinson's disease

KW - Ropinirole prolonged release

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84896718880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896718880&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.870152

DO - 10.1517/14740338.2014.870152

M3 - Article

C2 - 24490799

AN - SCOPUS:84896718880

VL - 13

SP - 383

EP - 389

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -